The price of Relmada Therapeutics Inc (NASDAQ:RLMD) shares last traded on Wall Street fell -28.57% to $0.45.
RLMD stock price is now -85.86% away from the 50-day moving average and -87.66% away from the 200-day moving average. The market capitalization of the company currently stands at $13.58M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target reduced from $23 to $1, Mizuho Downgraded its rating from Outperform to Neutral for Relmada Therapeutics Inc (NASDAQ: RLMD). On September 17, 2024, Jefferies Upgraded its previous ‘Hold’ rating to ‘Buy’ on the stock increasing its target price from $3.50 to quote $13, while ‘Goldman’ rates the stock as ‘Sell’
In other news, TRAVERSA SERGIO, Chief Executive Officer bought 51,407 shares of the company’s stock on Sep 11 ’24. The stock was bought for $153,707 at an average price of $2.99. Upon completion of the transaction, the Chief Executive Officer now directly owns 384,024 shares in the company, valued at $0.17 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Sep 09 ’24, Chief Executive Officer TRAVERSA SERGIO bought 55,579 shares of the business’s stock. A total of $150,619 was incurred on buying the stock at an average price of $2.71. This leaves the insider owning 299,603 shares of the company worth $0.13 million. A total of 16.58% of the company’s stock is owned by insiders.
During the past 12 months, Relmada Therapeutics Inc has had a low of $0.62 and a high of $7.22. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 6.89, and a quick ratio of 6.89. The fifty day moving average price for RLMD is $3.2411 and a two-hundred day moving average price translates $3.67325 for the stock.
The latest earnings results from Relmada Therapeutics Inc (NASDAQ: RLMD) was released for 2024-06-30.
